Somatrogon

Summary

Somatrogon (NGENLA) is a long-acting, once-weekly recombinant human growth hormone approved for the treatment of pediatric growth hormone deficiency (GHD). It offers a more convenient dosing schedule compared to daily somatropin injections while maintaining comparable efficacy and safety.

Mechanism of Action

Somatrogon is a recombinant human growth hormone (hGH) analog fused to three copies of the C-terminal peptide (CTP) of human chorionic gonadotropin beta-subunit. This fusion prolongs half-life by reducing renal clearance and slowing absorption, enabling once-weekly dosing. It binds and activates the GH receptor, stimulating IGF-1 production and downstream anabolic and growth-promoting effects.

Routes of Administration

Goals & Uses

• Improved Treatment AdherencePatient ConvenienceModerate
• Adult GHD TreatmentEndocrineLow
• Pediatric Growth Hormone Deficiency TreatmentEndocrine / GrowthHigh
• IGF-1 normalizationBiomarker / Surrogate EndpointHigh

Contraindications

• Prader-Willi syndrome with obesity/respiratory impairmentGenetic / RespiratoryHigh
• Active malignancyOncologyHighUse caution or avoid depending on agent and context
• Acute critical illnessCritical CareHigh
• Closed epiphysesSkeletalModerate
• Diabetic retinopathyOphthalmologyModerate
• Hypersensitivity to somatrogon or excipientsImmunologicalHigh

Adverse Effects

• Injection site reactionsLocalCommon
• HeadacheNeurologicCommonPain in the head or upper neck
• Intracranial hypertensionNeurologicalRare
• Slipped capital femoral epiphysisMusculoskeletalRare
• Arthralgia / myalgiaMusculoskeletalUncommon
• Elevated IGF-1 levelsEndocrine / LaboratoryCommon

Drug Interactions

• CYP450 substrates (e.g., cyclosporine, anticonvulsants)Low
• GlucocorticoidsModerate
• Insulin / antidiabetic agentsModerate
• Sex hormones (estrogens)Moderate

Population Constraints

• PregnancyReproductive SafetyRelative
• Hepatic impairmentOrgan FunctionRelative
• Renal impairmentOrgan ImpairmentRelative
• Neonates / infants < 2 yearsPediatricRelative
• AdultsAdult PopulationRelative

Regulatory Status

• European UnionApprovedApproved: Pediatric growth hormone deficiency in children and adolescentsEMA approved July 2022 as NGENLA; indicated for children ≥3 years.
• United StatesApprovedApproved: Pediatric growth hormone deficiency (GHD) in patients ≥3 years of ageFDA approved June 2023 as NGENLA; once-weekly subcutaneous injection.
• United KingdomApprovedApproved: Pediatric growth hormone deficiencyApproved by MHRA following EMA decision; available as NGENLA.

Approved by Health Canada in 2021, the EMA in 2022, and the FDA in 2023 for pediatric GHD. Marketed as NGENLA by Pfizer. Not approved for adult GHD or other indications as of current data.

Evidence & Sources

No sources recorded yet.